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Background: Indoleamine 2,3-dioxygenase (IDO) is an enzyme associated with the regulation 
of immune responses. Cytokines such as IFNγ induce its expression in endothelial cells origi-
nating from immune-privileged sites. In this study, we investigate regulators of IDO in primary 
endothelial cells from a non-immune-privileged site and determine whether IDO expression 
affects immune cell behavior.
Methods: IDO expression was determined using real-time quantitative polymerase chain 
reaction and immunoblotting. IDO activity was estimated using an IDO enzyme assay. Primary 
cells were transfected using microporation, and T-cell migration was determined using a cell 
transmigration assay.
Results: IDO is expressed in human saphenous vein endothelial cells after stimulation with 
IFNγ but not after treatment with TNFα, IL-1β, IL-2, IL-4, IL-6, or IL-10. VEGFβ and heparin 
negatively regulate IFNγ-driven increases in IDO. Overexpression of IDO in endothelial cells 
does not affect transmigration of T-cells.
Conclusion: IDO is expressed in human saphenous vein endothelial cells after stimula-
tion with IFNγ. Heparin and angiogenesis stimulators such as VEGFβ negatively regulate its 
expression.
Keywords: IFNγ, VEGFβ, endothelium, inflammation, HSVEC
Introduction
The endothelial cell plays a central role in the control of inflammatory processes and 
can be involved in graft rejection, atherosclerosis, and vasculitides.1–3 In addition to the 
effect of endothelial cells in the recruitment of leukocytes into inflammation sites,4,5 
they can also present antigens to white blood cells influencing their activation and 
transmigration.6–9
Indoleamine 2,3-dioxygenase (IDO) is an intracellular heme-containing enzyme that 
catalyzes the oxidative cleavage of the indole ring of l-tryptophan to produce kynure-
nine metabolites.10 Depletion of l-tryptophan from the local microenvironment together 
with the production of kynurenine can modulate inflammation responses.11,12 IDO 
activation has been associated with antimicrobial effects and the modulation of T-cell 
responses,13 at least partly by enhancement of proliferation of regulatory T-cells.14,15 
Increased expression of IDO is related to a favorable environment for tumor growth 
and graft survival,16–19 the pathophysiology of depression,20,21 and protection against 
pulmonary hypertension.22 IDO activity may be affected not only at the transcriptional 
and translational level, but also by posttranslational modification and SOCS3-associated 
differential degradation.23–25
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What is currently not known is whether immune-
regulatory molecules such as IDO mediate graft rejection 
exhibited by endothelial cells. When human umbilical vein 
endothelial cells (HUVECs) were stimulated with IFNγ, 
IDO expression and activity were increased. In addition, it 
was shown that IDO activity inhibition enhanced the abil-
ity of HUVECs to stimulate allogeneic T-cell responses.26 
Treatment of cells originating from non-immune-privileged 
sites such as human saphenous vein endothelial cells 
(HSVECs) with IFNγ did not upregulate IDO.26 In a non-
vascular in vitro model of human corneal endothelial cells 
(HCECs) IFNγ-driven upregulation of IDO had no effect on 
T cell proliferation.27 In this study, we used primary cells 
isolated from a non-immune-privileged source, the saphen-
ous vein, to investigate factors that affect IDO regulation 
and determined whether forced expression of IDO in these 
cells affected immune cell migration.
Materials and methods
Isolation of primary endothelial  
cells from human saphenous veins
Primary endothelial cells from human saphenous veins 
were isolated using the method described elsewhere.28 
Briefly, both ends of the vein were sutured and the lumen 
was filled with 10 mL prewarmed 1 mg/mL collagenase 
II solution (Sigma-Aldrich Co, St Louis, MO, USA) and 
incubated at 37°C for 10 minutes. Then collagenase II 
solution was collected and vein was flushed with 10 mL 
trypsin– ethylenediaminetetraacetic acid and the effluent 
was collected again. Cells were pelleted and plated in a 
T25 flask. Endothelial cells were further purified with anti-
CD105 microbeads using MS columns (Miltenyi Biotech, 
Auburn, CA, USA). Cell fractions showing high levels of 
staining for von Willebrand factor were used.
cell culture and propagation
Cells were maintained in a subconfluent monolayer at 37°C 
in a humidified atmosphere containing 5% CO
2
.  Endothelial 
medium was prepared by combining equal volumes of 
endothelial SFM (Thermo Fisher Scientific, Waltham, MA, 
USA) and endothelial EGM2 medium (Walkersville, MD, 
USA) and adding per 500 mL medium 5 mL of  penicillin/
streptomycin, 5 mL glutamine, and 5 mL of 5 mg/mL endothe-
lial cell growth supplement purchased from BD Biosciences 
(San Jose, CA, USA). They were subcultured using trypsin, 
and screening for mycoplasma contamination was carried 
out on a regular basis. For experimental use, cells were 
treated with recombinant human IFNγ, recombinant human 
TNFα, recombinant human IL-2, recombinant human IL-4, 
recombinant human IL-6, recombinant human IL-10, and 
recombinant human VEGFβ, all purchased from Peprotech 
(Rocky Hill, NJ, USA).
IDO activity assay
IDO activity was determined in wells exhibiting cell conflu-
ency greater than 70% using a colorimetric assay based on 
detection of kynurenine as described previously.29,30 Briefly, 
l-kynurenine standards (0–200 µM) were prepared in 
endothelial medium. Kynurenine in control, test, and standard 
samples was precipitated by incubation with 30% trichloroa-
cetic acid at 50°C for 30 minutes and centrifuged at 2,000× g 
for 10 minutes. Visualization of signal took place by adding 
equal volumes of Ehrlich reagent to the supernatant and incu-
bation at 65°C for 15 minutes. Ehrlich reagent was prepared 
using 6.2 mL 1-propanol, 1.5 mL distilled water, 2.6 mL of 
70% perchloric acid, and 1.5 g of 4-dimethylbenzinamide, all 
purchased from Sigma-Aldrich Co. Absorbance was measured 
at 492 nm in a colorimetric plate reader.
cell homogenization  
and Western blotting
Control and treated cells were harvested from flasks, washed 
in phosphate-buffered saline, and lysed in SDS sample buffer 
(62.5 mM Tris-HCl, pH 6.8, 2% w/v SDS, 10% glycerol, 50 
mM DTT, and 0.01% bromophenol blue) for 5 minutes on ice 
and sonicated for 10–15 seconds. Samples were then heated 
for 5 minutes at 90°C, micro-centrifuged briefly, and stored at 
-20°C. Antibodies against IDO and SOCS3 were purchased 
from Abcam (Cambridge, UK). Primary antibody of interest 
diluted in blocking buffer (1.5% milk in Tris-buffered saline/
Tween 20, pH 7.6) containing 5% BSA was added to the mem-
branes and left incubating overnight at 4°C. Membranes were 
then washed and incubated with secondary antibody. Signal 
was visualized on X-ray films using ECL Western blotting 
reagents (Amersham  Biosciences, Little Chalfont, UK).
Real-time polymerase chain reaction
Cells were washed with phosphate-buffered saline, and 
mRNA was obtained using TRIzol. cDNA was obtained 
using the SuperScript First-Strand Synthesis System for 
RT-PCR. Detection of product was made using SYBR Green 
(Thermo Fisher Scientific). Relative quantification of mRNA 
transcription was performed by normalizing the Ct value of 
IDO to the Ct value of actin in control:
 dCtcontrol = Ctido - Ctactin (1)
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and treated cells:
 dCttreated = Ctido - Ctactin (2)
Then the ∆∆Ct product was calculated by subtracting 
the dCt value of controls from the dCt value of treated 
cells:
	 ∆∆Ct = dCttreated - dCtcontrol (3)
Using the formula 2-∆∆Ct, the relative enhance-
ment ratio of IDO transcription was estimated. The 
following primer sequences were used: HPRT for-
ward: 5′-GCAGACTTTGCTTTCCTTGGTC-3′; HPRT 
reverse: 5′-CTGGCTTATATCCAACACTTCGTG-3′; IDO 
forward: 5′-GGTCATGGAGATGTCCGTTAA-3′; IDO 
reverse: 5′-ACCAATAGAGAGACCAGGAAGAA-3′.
Transfection of endothelial  
cells using microporation
Microporation apparatus, tips, buffers and the MP-1096 
kit were purchased from Labtech International (Ringmer, 
UK). The desired number of cells were resuspended 
in 24 µL of microporation suspension buffer and kept 
at 4°C for the duration of the experiment. One micro-
gram DNA was added and cells were transfected using 
microporation. The vectors used were pcDNA3.1 (empty 
vector), pSMART2G (empty vector), pcDNA3.1-EGFP, 
and pSMART2G-IDO. Voltage was set at 1,350 mV, pulse 
number at 1, and duration at 30 ms, and p10 tips were used. 
After microporation, cell aliquots were put in endothelial 
medium in 24-well plates at 37°C and left to incubate 
overnight. For experiments, cells were used in the first 3 
days after transfection.
Transmigration assay
HSVECs were plated on a 24-well Transwell chamber at 
full confluence and left to incubate for 1 day. PBMCs were 
obtained from human donors or buffy coat using density 
centrifugation with Ficoll-Paque. T-cells were obtained from 
PBMCs using MACS bead separation, employing negative 
selection with biotin-conjugated antibodies against CD14, 
CD16, CD19, CD36, CD56, and CD235. Fractions were 
stained with CD3 fluorescein isothiocyanate to determine 
purity and those staining positive were used for experiments. 
T-cell fractions containing 3×105 cells were applied in 1:10 
dilution on the top of the endothelial cells in the Transwell 
chambers and co-cultured for a further day. T-cells transmi-
grating through the endothelial monolayer were collected 
on the bottom chamber and their number determined using 
a hemocytometer.
statistical analysis of results
Results are presented as means + standard error of the mean. 
Statistical significance was carried out using a t-test assuming 
one-tailed distribution using two-sample unequal variance. 
P,0.05 was considered as a statistically significant value. 
Microsoft Excel data processing functions were used for data 
processing and analysis.
Results
IFnγ is the main regulator of IDO 
expression in primary hsVecs
Differential regulation of IDO in endothelial cells stimu-
lated with IFNγ was evident in other studies depending on 
the endothelial cell origin.26,27 To demonstrate whether IDO 
expression in primary HSVECs was increased after IFNγ 
stimulation, these primary cells were treated with concen-
trations of IFNγ (0–120 ng/mL) for 2 days. IDO expression 
was assessed using immunoblotting, and IDO activity was 
assessed using an IDO activity assay. Results show that treat-
ment of HSVECs with IFNγ (80 ng/mL) resulted in increased 
IDO expression and IDO activity (Figures 1 and S1).
To investigate what other regulators drive expres-
sion of IDO, HSVECs were treated with IFNγ alone or in 
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Figure 1 IFnγ upregulates IDO in primary human saphenous vein endothelial cells 
(hsVecs).
Notes: cells were treated with IFnγ (80 ng/ml) for 2 days. IDO expression 
levels were assessed using immunoblotting, and IDO activity was assessed using 
the l-kynurenine IDO activity assay. Results show that IDO protein levels (A) 
and IDO activity (B) are increased after hsVecs are stimulated with IFnγ for 
2 days. Immunoblotting data (A) are presented as a representative blot of three 
experiments and kynurenine activity assay (B) is presented as means + standard 
error of the mean (n=4). *P,0.05.
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combination with cytokines in relevant concentrations such 
as TNFα (80 ng/mL), IL-1β (20 ng/mL), IL-2 (20 ng/mL), 
IL-4 (40 ng/mL), IL-6 (40 ng/mL), IL-10 (40 ng/mL), and 
TGFβ (100 ng/mL) for 2 days. IDO mRNA expression was 
assessed using real-time quantitative polymerase chain 
reaction. Results show that IDO mRNA was increased after 
treatment with IFNγ but not after treatment with the other 
cytokines (Figure 2A). In addition, co-treatment of HSVECs 
with IFNγ and these cytokines did not result in significant 
change in IFNγ-driven increases in IDO expression and activ-
ity, suggesting that IFNγ was the main regulator of IDO in 
HSVECs (Figures 2B and S2).
VegF, heparin, and nitric oxide are 
negative regulators of IDO in hsVecs
IFNγ has exhibited antiangiogenic effects in human cornea by 
downregulating expression of VEGFα.31 To identify whether 
crosstalk of IFNγ and VEGF pathways exists in HSVECs, 
these cells were stimulated with IFNγ (80 ng/mL) alone 
or in combination with VEGFβ (40 ng/mL) for 1 day and 
2 days. Expression of IDO was determined using immuno-
blotting with a monoclonal antibody against human IDO. 
IDO was not expressed in unstimulated cells or cells treated 
with VEGFβ only (data not shown). When HSVECs were 
treated with IFNγ, then IDO protein levels were increased, 
whereas co-treatment of HSVECs with IFNγ and VEGFβ 
decreased IDO levels relative to stimulation with IFNγ only 
(Figure 3A). SOCS3 has been shown to target IDO for pro-
teasomal degradation.25 To investigate the possibility that 
SOCS3 protein levels are regulated in a similar manner to 
IDO’s protein levels, its expression was investigated using 
immunoblotting. SOCS3 protein levels remained unchanged 
in cells treated with IFNγ only. However, when cells were 
co-treated with IFNγ and VEGFβ, SOCS3 protein levels 
increased after 24 hours and completely eliminated after 
48 hours (Figure 3A).
We have previously used heparin in the culture of 
endothelial cells and questioned whether it interferes with 
the induction of IDO.26 For this purpose, we measured 
the IDO response to IFNγ in the presence and absence of 
heparin. HSVECs were stimulated with IFNγ (80 ng/mL) 
with or without cell culture-relevant concentrations of 
heparin (1 mg/mL and 2 mg/mL). IDO activity was assessed 
using an IDO activity assay. This concentration of heparin 
was chosen because it is detected in endothelial cell media. 
Results show that heparin abrogated IFNγ-driven increases 
in IDO activity (Figure 3B).
Differential regulation of IDO activity by nitric oxide 
(NO) has been shown in monocyte-derived macrophages 
but not in microglial cells.32 To investigate whether NO has 
a regulatory effect on IDO activity in HSVECs, cells were 
stimulated with IFNγ (80 ng/mL) with or without the NO 
donor DetaNO (10 µM and 50 µM). IDO expression levels 
were assessed using immunoblotting and IDO activity was 
assessed using the IDO activity assay. Results show that NO 
decreased IFNγ-driven increases in IDO activity. However, 
IDO protein levels did not follow the same regulation pattern 
(Figure 3C and D).
Increased expression of IDO  
in hsVecs does not affect T-cell 
transmigration properties
To determine the effect of IDO overexpressed in endothelial 
cells independently of IFNγ stimulation, primary HSVECs 
were transiently transfected with EGFP using microporation. 
EGFP fluorescence was detected up to 6 days using fluores-
cence microscopy (Figure 4A). Then, HSVECs were tran-
siently transfected with an IDO plasmid. Overexpression of 
IDO was confirmed using immunoblotting (Figure 4B). IDO-
overexpressing HSVECs were plated on Transwell chambers 
and left to incubate for 1 day. T-cells were then added in 
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Figure 2 IFnγ is the main regulator of IDO in human saphenous vein endothelial 
cells (hsVecs).
Notes: cells were treated with IFnγ (80 ng/ml), TnFα (80 ng/ml), Il1β (20 ng/
ml), Il2 (20 ng/ml), Il4 (40 ng/ml), Il6 (40 ng/ml), Il10 (40 ng/ml), and TgFβ (100 
ng/ml) either alone or in combination for 2 days. IDO expression was determined 
using real-time quantitative polymerase chain reaction. Results show that only IFnγ 
significantly increases expression of IDO in hsVecs (A). co-treatment of cells with 
IFnγ and the other cytokines did not result in changes in IFnγ-driven increases in 
IDO expression (B). Results are presented as the means of three experiments + 
standard error of the mean. *P,0.05.
Journal of Inflammation Research 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
101
Regulation of IDO in endothelium
the Transwell chambers and coincubated with HSVECs for 
24 hours further. The number of cells detected in the lower 
compartment of the Transwell chamber was counted using 
a hemocytometer. Results show that IDO overexpression in 
HSVECs did not affect the number of T-cells transmigrating 
through the endothelial cell monolayer barrier (Figure 4C).
Discussion
IDO is an enzyme that metabolizes tryptophan and is known 
to be central in the regulation of immune responses. IDO can 
be expressed in endothelial cells and alters T-cell responses to 
the endothelium. The aim of this study was to identify regula-
tors of IDO expression in HSVECs and to determine whether 
IDO expression in these primary cells pooled together from 
different donors affects inflammation-related processes.
HSVECs were treated with proinflammatory and anti-
inflammatory cytokines. IDO transcription and protein 
levels and activity were then assessed. We were not able to 
detect IDO expression in endothelial cells cultured under 
normal conditions. Stimulation of HSVECs with different 
concentrations of TNFα, IL-1β, IL-2, IL-4, IL-6, and IL-10 
either alone or in combinations had a negligible effect on 
IDO expression that did not result in a significant func-
tional effect as determined by production of kynurenines 
(data not shown).  However, stimulation of cells with IFNγ 
resulted in an increase in IDO expression and activity. The 
high concentrations of IFNγ used to achieve upregulation of 
IDO in HSVECs did not result in detrimental effects to the 
cells. Co-stimulation of IFNγ-treated endothelial cells with 
cytokines such as TNFα, IL-1β, IL-2, IL-4, IL-6, and IL-10 
did not affect IDO expression and activity relative to cells 
treated with IFNγ.
Conflicting reports on the ability of HSVECs to increase 
IDO expression after treatment with IFNγ have been reported, 
and we have described that IFNγ is unable to upregulate 
IDO activity in HSVECs while confirming upregulation in 
HUVECs.26 However, those previous experiments were per-
formed with heparin as an additive to endothelial cell media 
to enhance cell proliferation and survival. To investigate 
whether heparin affects IFNγ-driven increases in IDO activity 
in HSVECs we replaced heparin with endothelial cell growth 
supplement factors, golden grade fetal calf serum and used 
specialized endothelial cell medium. By optimizing these cell 
culture conditions no significant loss of endothelial cell viabil-
ity was observed. In addition HSVECs confluency was greater 
than 70% in experimental conditions. Using these experimental 
conditions we have shown that heparin, in concentrations rou-
tinely used in cell culture and experimental media, counteracts 
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the ability of IFNγ to upregulate IDO in HSVECs. Heparin 
interferes with IFNγ activity by binding to the cytokine and 
reducing its ability to bind and activate the IFNγ receptor.33,34 
Heparin counteracts IFNγ-induced increases of iNOS in rat 
endothelial cells,35 apoptosis of primary trophoblasts,36 and 
fractalkine expression in human endothelial cells.37  These 
results suggest that endothelial cells located in non- immune-
privileged tissues can exhibit induction of IDO activity after 
IFNγ stimulation in a similar manner to the endothelial cells 
associated with immune-privileged tissue.
VEGFα has been associated with IDO expression upregu-
lation in prostaglandin E2- and TNFα-treated dendritic cells.38 
In addition, IFNγ has exhibited antiangiogenic effects in human 
cornea by downregulating expression of VEGFα.31 In this 
study, we show for the first time that angiogenesis stimula-
tors such as VEGFβ have a negative effect on IFNγ-driven 
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Figure 4 IDO does not affect T-cell transmigration properties.
Notes: human saphenous vein endothelial cells (hsVecs) were transfected with pcDna3.1-egFP and signal was detected up to 6 days after transfection. hsVecs were then 
transiently transfected with psMaRT2g-IDO. Transfected cells were plated in Transwell chambers and left to incubate for 1 day. T-cells were then added and incubation was 
continued for a further day. T-cells transmigrated through the endothelial monolayer were then counted using a hemocytometer. Results show that IDO does not affect the 
number of T-cells transmigrating through the endothelial cell barrier. Results are presented as an average of one experiment that was repeated three times with similar results.
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increases in IDO expression and also regulate SOCS3 protein 
levels. Orabona et al and Pallota et al have shown that SOCS3 
mediates proteasome degradation of IDO in dendritic cells.25,39 
It is tempting to hypothesize that the same mechanism takes 
place in primary endothelial cells co-treated with VEGFβ and 
IFNγ. However, further research is needed to prove a direct 
link between VEGFβ and SOCS3-mediated proteasome deg-
radation of IDO. NO has been shown to affect IDO activity in 
monocyte-derived macrophages at the posttranslational levels 
but not in other biological models such as microglial cells.32 
In our study, we confirm that NO has a negative effect on IDO 
activity at the posttranslational level. IDO catabolizes trypto-
phan by inserting oxygen to generate N-formyl-kynurenine. 
NO may inhibit this function by displacing bound tryptophan 
and oxygen after binding to IDO’s active heme site.40
The recruitment of inflammatory leukocytes from 
blood vessels is controlled by the expression of adhesion 
molecules on the endothelium as well as the secretion and 
presentation of chemokines.26 To determine whether IDO 
expression in HSVECs affected T-cell transmigration, IDO 
was overexpressed in these cells using microporation. This 
method resulted in transfection efficiency of approximately 
50% that is stable for at least 6 days. Transfected HSVECs 
were allowed to attach onto Transwell chambers and form 
a monolayer. The number of T-cells transmigrating through 
the endothelial monolayer transfected with IDO versus the 
number of T-cells transmigrating through the endothelial cells 
expressing basal levels of IDO was then determined. Using 
this technique, we were not able to demonstrate a significant 
change in T-cell transmigration. It is possible that the number 
of non-transfected cells in the monolayer was high enough 
to allow passage of T-cells. However, controls using IFNγ-
treated HSVECs did not result in a significant change in the 
number of transmigrated cells.
IDO regulates immune responses which otherwise could 
cause tissue damage. The endothelial cell is one of the first 
contacts of an activated lymphocyte, hence whether it has 
the mechanistic capability to increase IDO expression and 
regulate the immune response is highly significant. Max et al 
have demonstrated that IFNγ-induced IDO expression in Ewing 
sarcoma cells decreased T-cell proliferation in co-culture assays 
3 days after treatment, but no effect on T-cell proliferation was 
evident 1 day after treatment.41 In contrast, Lahdou et al have 
shown that upregulation of IDO in corneal endothelial cells does 
not affect T-cell proliferation.27 In addition, they demonstrated 
that extraordinarily high levels of l-kynurenine close to 400 µM 
are necessary for a suppressive effect on T-cell proliferation 
to be detected. In our study, we achieved relatively low levels 
of l-kynurenine concentration up to 10 µM (transfected cells) 
(data not shown) and 40 µM (IFNγ-treated cells) when assessed 
in 24-well plates. However, the levels of IFNγ used in our study 
were higher than the physiological levels of IFNγ found in blood 
serum of patients treated for infections, although it cannot be 
excluded that higher levels of IFNγ accumulate in the target 
tissue’s microenvironment. So we believe that, with our chosen 
experimental procedures, we do not underestimate the IFNγ 
concentration and IDO expression the in vivo endothelial cells 
may be subjected to. In addition, it is important to distinguish 
between effects on cell proliferation and direct effects on trans-
migration properties of the cells. It is possible that the duration 
of lymphocyte exposure and the concentration of kynurenines 
the lymphocytes are subjected to, in the microenvironment of 
IDO-overexpressing cells, may dictate T-cell response. It is of 
interest to establish whether IDO may have additional roles in 
endothelium. Park et al have suggested that the role of IDO is 
different between target tissues and infiltrated immune cells 
while demonstrating that low endothelial IDO levels correlate 
with lower non-relapse mortality in patients with acute graft-
versus-host disease after allogeneic hematopoietic stem cell 
transplantation.42 Wang et al have shown in mouse models of 
systemic inflammation that IDO expressed in vascular endothe-
lial cells results in the production of kynurenines which regulate 
vascular tone and blood pressure regulation.43
The data presented in this study build on previous pub-
lished observations and altogether provide an insight into 
the mechanism by which endothelial cells regulate immune 
responses and the role of endothelial IDO. Our results show 
that HSVECs have the capability to upregulate IDO after 
stimulation with IFNγ but, at relatively low kynurenine 
concentrations, do not directly affect T-cell transmigration 
properties. We also show for the first time that angiogenesis 
stimulators negatively regulate the IFNγ-driven increases in 
IDO expression. Given the interest that exists in IDO and graft 
survival, it is of interest to investigate whether angiogenesis 
regulators can promote or inhibit graft survival in vivo and the 
possibility that this might be an IDO-dependent effect.
Acknowledgment
This study was funded by the British Heart Foundation (BHF).
Disclosure
The authors report no conflicts of interest in this work.
References
1. Manduteanu I, Simionescu M. Inflammation in atherosclerosis: 
a cause or a result of vascular disorders? J Cell Mol Med. 2012;16(9): 
1978–1990.
Journal of Inflammation Research 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
104
Mouratidis and george
 2. Biasucci LM, Cardillo MT. Biomarkers of inflammation and endothelial 
function: the holy grail of experimental and clinical medicine? Vascul 
Pharmacol. 2012;56(1–2):26–28.
 3. Sis B. Endothelial molecules decipher the mechanisms and func-
tional pathways in antibody-mediated rejection. Hum Immunol. 
2012;73(12):1218–1225.
 4. Daniel AE, van Buul JD. Endothelial junction regulation: 
a prerequisite for leukocytes crossing the vessel wall. J Innate Immun. 
2013;5(4):324–335.
 5. Heemskerk N, van Rijssel J, van Buul JD. Rho-GTPase signaling 
in leukocyte extravasation: an endothelial point of view. Cell Adh 
Migr. 2014;8(2):67–75. 
 6. Charreau B. Molecular regulation of endothelial cell activation: novel 
mechanisms and emerging targets. Curr Opin Organ Transplant. 
2011;16(2):207–213.
 7. Mai J, Virtue A, Shen J, Wang H, Yang XF. An evolving new para-
digm: endothelial cells – conditional innate immune cells. J Hematol 
Oncol. 2013;6:61.
 8. Muller WA. Getting leukocytes to the site of inflammation. Vet 
Pathol. 2013;50(1):7–22.
 9. Marelli-Berg FM, Frasca L, Weng L, Lombardi G, Lechler RI. Antigen 
recognition influences transendothelial migration of CD4+ T cells. 
J Immunol. 1999;162(2):696–703.
 10. Fallarino F, Grohmann U, Puccetti P. Indoleamine 2,3-dioxygenase: 
from catalyst to signaling function. Eur J Immunol. 2012;42(8): 
1932–1937.
 11. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic 
fetal rejection by tryptophan catabolism. Science. 1998;281(5380): 
1191–1193.
 12. Mellor AL, Sivakumar J, Chandler P, et al. Prevention of T cell-driven 
complement activation and inflammation by tryptophan catabolism 
during pregnancy. Nat Immunol. 2001;2(1):64–68.
 13. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamoto Y, Saito K. 
Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metab-
olites in infectious diseases: potential role in macrophage- mediated 
inflammatory diseases. Mediators Inflamm. 2013;2013:391984.
 14. Schmetterer KG, Neunkirchner A, Pickl WF. Naturally occurring regu-
latory T cells: markers, mechanisms, and manipulation. FASEB J. 
2012;26(6):2253–2276.
 15. Sant AJ, Chaves FA, Leddon SA, Tung J. The control of the specificity 
of CD4 T cell responses: thresholds, breakpoints, and ceilings. Front 
Immunol. 2013;4:340.
 16. Munn DH. Blocking IDO activity to enhance anti-tumor immunity. 
Front Biosci (Elite Ed). 2012;4:734–745.
 17. Dürr S, Kindler V. Implication of indolamine 2,3 dioxygenase in the 
tolerance toward fetuses, tumors, and allografts. J Leukoc Biol. 2013; 
93(5):681–687.
 18. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in 
 cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72(21): 
5435–5440.
 19. Johnson TS, Munn DH. Host indoleamine 2,3-dioxygenase: con-
tribution to systemic acquired tumor tolerance. Immunol Invest. 
2012;41(6–7):765–797.
 20. Catena-Dell’Osso M, Rotella F, Dell’Osso A, Fagiolini A, Marazziti D. 
Inflammation, serotonin and major depression. Curr Drug Targets. 
2013;14(5):571–577.
 21. Mándi Y, Vécsei L. The kynurenine system and immunoregulation. 
J Neural Transm. 2012;119(2):197–209.
 22. Xiao Y, Christou H, Liu L, et al. Endothelial indoleamine 2,3-
 dioxygenase protects against development of pulmonary hypertension. 
Am J Respir Crit Care Med. 2013;188(4):482–491.
 23. Fujigaki S, Saito K, Takemura M, et al. L-tryptophan-L-kynurenine 
pathway metabolism accelerated by Toxoplasma gondii infection is 
abolished in gamma interferon-gene-deficient mice: cross-regulation 
between inducible nitric oxide synthase and indoleamine-2,3- 
dioxygenase. Infect Immun. 2002;70(2):779–786.
 24. Oh GS, Pae HO, Choi BM, et al. 3-Hydroxyanthranilic acid, one of 
metabolites of tryptophan via indoleamine 2,3-dioxygenase pathway, 
suppresses inducible nitric oxide synthase expression by enhancing 
heme oxygenase-1 expression. Biochem Biophys Res Commun. 2004; 
320(4):1156–1162.
 25. Orabona C, Pallotta MT, Volpi C, et al. SOCS3 drives proteasomal 
degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes 
IDO-dependent tolerogenesis Proc Natl Acad Sci U S A. 2008;105(52): 
20828–20833.
 26. Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, 
George AJ. Expression of indoleamine 2,3-dioxygenase (IDO) by 
endothelial cells: implications for the control of alloresponses. Am J 
Transplant. 2006;6(6):1320–1330.
 27. Lahdou I, Engler C, Mehrle S, et al. Role of human corneal endothelial 
cells in T-cell-mediated alloimmune attack in vitro. Invest Ophthalmol 
Vis Sci. 2014;55(3):1213–1221.
 28. Mouratidis PX, George AJ. Transfection of indoleamine 2,3 dioxygenase 
in primary endothelial cells. Methods Mol Biol. 2010;616: 149–159.
 29. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon-
gamma action. Characterization of indoleamine 2,3-dioxygenase in 
cultured human cells induced by interferon-gamma and evaluation of 
the enzyme-mediated tryptophan degradation in its anticellular activity. 
J Biol Chem. 1988;263(4):2041–2048.
 30. Alegre E, López AS, González A. Tryptophan metabolites interfere 
with the Ehrlich reaction used for the measurement of kynurenine. Anal 
Biochem. 2005;339(1):188–189.
 31. Kommineni VK, Nagineni CN, William A, Detrick B, Hooks JJ. 
IFN-gamma acts as anti-angiogenic cytokine in the human cornea by 
regulating the expression of VEGF-A and sVEGF-R1. Biochem Biophys 
Res Commun. 2008;374(3):479–484.
 32. Alberati-Giani D, Malherbe P, Ricciardi-Castagnoli P, Köhler C, 
Denis-Donini S, Cesura AM. Differential regulation of indoleamine 
2,3-dioxygenase expression by nitric oxide and inflammatory media-
tors in IFN-gamma-activated murine macrophages and microglial cells. 
J Immunol. 1997;159(1):419–426.
 33. Sarrazin S, Bonnaffé D, Lubineau A, Lortat-Jacob H. Heparan sulfate 
mimicry: a synthetic glycoconjugate that recognizes the heparin bind-
ing domain of interferon-gamma inhibits the cytokine activity. J Biol 
Chem. 2005;280(45):37558–37564.
 34. Fluhr H, Spratte J, Heidrich S, Ehrhardt J, Steinmüller F, Zygmunt M. 
Heparin inhibits interferon-γ signaling in human endometrial stromal 
cells by interference with the cellular binding of interferon-γ. Fertil 
Steril. 2011;95(4):1272–1277.
 35. Bonmann E, Jüttler E, Krestel HE, Spranger M. Heparin inhibits induc-
tion of nitric oxide synthase by cytokines in rat brain microvascular 
endothelial cells. Neurosci Lett. 1998;253(2):95–98.
 36. Hills FA, Abrahams VM, González-Timón B, et al. Heparin 
 prevents programmed cell death in human trophoblast. Mol Hum 
Reprod. 2006;12(4):237–243.
 37. Hatakeyama M, Imaizumi T, Tamo W, et al. Heparin inhibits IFN-
gamma-induced fractalkine/CX3CL1 expression in human endothelial 
cells. Inflammation. 2004;28(1):7–13.
 38. Marti LC, Pavon L, Severino P, Sibov T, Guilhen D, Moreira-Filho CA. 
Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxy-
genase expression by dendritic cells and subsequently impacts lympho-
cyte proliferation. Mem Inst Oswaldo Cruz. 2013;109(1):70–79.
 39. Pallotta MT, Orabona C, Volpi C, Grohmann U, Puccetti P, Fallarino F. 
Proteasomal degradation of indoleamine 2,3-dioxygenase in CD8 den-
dritic cells is mediated by suppressor of cytokine signaling 3 (SOCS3). 
Int J Tryptophan Res. 2010;3:91–97.
 40. Thomas SR, Terentis AC, Cai H, et al. Post-translational regulation 
of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol 
Chem. 2007;282(33):23778–23787.
 41. Max D, Kühnöl CD, Burdach S, Niu L, Staege MS, Föll JL. Indoleamine- 
2,3-dioxygenase in an immunotherapy model for Ewing sarcoma. 
Anticancer Res. 2014;34:6431–6441.
Journal of Inflammation Research 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
105
Regulation of IDO in endothelium
 42. Park G, Choia YJ, Lee SE, et al. A paradoxical pattern of indoleamine 
2,3-dioxygenase expression in the colon tissues of patients with acute 
graft-versus-host disease. Exp Hematol. 2014;42:734–740.
 43. Wang Y, Liu H, McKenzie GK etal. Kynurenine is an endothelium-
derived relaxing factor produced during inflammation. Nat Med. 
2010;16(3):279–285.
Journal of Inflammation Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-inflammation-research-journal
The Journal of Inflammation Research is an international, peer-reviewed 
open-access journal that welcomes laboratory and clinical findings on the 
molecular basis, cell biology and pharmacology of inflammation including 
original research, reviews, symposium reports, hypothesis formation and 
commentaries on: acute/chronic inflammation; mediators of inflamma-
tion; cellular processes; molecular mechanisms; pharmacology and novel 
anti-inflammatory drugs; clinical conditions involving inflammation. 
The manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Journal of Inflammation Research 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
106
Mouratidis and george
IDO activity dose–response curve detected
2 days after treatment
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Figure S1 IDO dose–response curve.
Note: Results are presented as means + standard deviation of one experiment.
0
5
10
15
20
25
30
35
K
yn
u
re
n
in
e
co
n
ce
n
tr
at
io
n
 (
µM
)
IFNγ IFNγ
+ IL2
IFNγ
+ IL4
IFNγ
+ IL6
IFNγ
+ IL10
IFNγ
+ TGF β
Control
Figure S2 IDO activity after treatment of human saphenous vein endothelial cells 
with cytokines for 2 days.
Note: Results are presented as means + standard deviation of one experiment.
Supplementary materials
